Results 151 to 160 of about 249,854 (357)

Pre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting.
Kimberley I. Hemelrijk   +23 more
wiley   +1 more source

Feasibility and Safety of Distal Transradial Access in Patients With Out‐of‐Hospital Cardiac Arrest Undergoing Emergency PCI: A Single‐Center Retrospective Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Distal transradial access (dTRA) has gained attention for its lower risk of vascular complications compared to conventional transradial access (TRA). However, its feasibility and safety in patients with out‐of‐hospital cardiac arrest (OHCA) undergoing emergency percutaneous coronary intervention (PCI) remain uncertain.
Shiori Kawakami   +9 more
wiley   +1 more source

A Systematic Review and Meta-Analysis on the Safety of Antiplatelet Discontinuation Following Stent-Assisted Coil Embolization for Cerebral Aneurysms

open access: yesNeuroSci
Background: Stent-assisted coil embolization (SACE) is a common endovascular technique for managing intracranial aneurysms. The permanent presence of a stent inside the cerebral artery necessitates the postoperative use of antiplatelets.
Mohammed Maan Al-Salihi   +6 more
doaj   +1 more source

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2022
C. Bradbury   +72 more
semanticscholar   +1 more source

Cerebrovascular Events in Aortic Stenosis: From Native Valve Disease to TAVR‐Specific Risk and Prevention

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Aortic stenosis (AS) is associated with a heightened burden of cardiovascular comorbidities, atrial fibrillation (AF), and progressive valvular calcification, all of which may contribute to cerebrovascular events across the disease continuum.
Priyanka Boettger   +7 more
wiley   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang   +9 more
wiley   +1 more source

The Multifaceted Effects of Non-Steroidal and Non-Opioid Anti-Inflammatory and Analgesic Drugs on Platelets: Current Knowledge, Limitations, and Future Perspectives

open access: yesPharmaceuticals
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely utilized pharmaceuticals worldwide. Besides their recognized anti-inflammatory effects, these drugs exhibit various other pleiotropic effects in several cells, including platelets ...
Alexandros Tsoupras   +5 more
doaj   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao   +8 more
wiley   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy